An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

NCT07357597 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Stomatitis

Interventions

DRUG: Dexamethasone mouthwash
DRUG: Datopotamab Deruxtecan (Dato-DXd)

Sponsor

AstraZeneca

Collaborators

[object Object]